Background: Understanding the future health disparity burden of cardiometabolic diseases across racial-ethnic and socioeconomic (SES) groups is essential for policy and priority setting.

Methods: Using a validated US Diabetes, Obesity, Cardiovascular Disease microsimulation (DOC-M) model, we predicted absolute and relative changes (Δ) in the prevalence of diabetes, obesity, cardiovascular diseases (CVD), and all-cause mortality over the next 20 years, overall and by racial-ethnic and SES groups (education and income) among the US population aged 40-79 using the NHANES 2017-2020 data (n=5,745, representing 142.5 million).

Results: As the population aged over the next 20 years, our model predicted that all-cause mortality reached 40.9% overall, with the largest increase in non-Hispanic Black adults (46.7%), followed by adults with less than high school education (44.3%). CVD was projected to increase most in Hispanic adults (11.0% to 23.4%, Δ=↑113.5%), adults with high school equivalent education (18.4% to 33.4%, Δ=↑81.7%), and middle-income adults (16.1% to 29.2%, Δ=↑80.9%). Diabetes prevalence would grow the fastest among Hispanic adults (24.3% in 2020 to 52.9% in 2040, Δ=↑118.3%), versus Non-Hispanic Black adults (23.7% to 45.0%, Δ=↑90.2%) and Non-Hispanic White adults (17.1% to 30.0%, Δ=↑75.5%). Although diabetes prevalence would grow fastest among college-educated adults (16.5% to 31.2%, Δ=↑89.3%) and high-income adults (16.1% to 30.3%, Δ=↑88.0%), the greatest burden of diabetes remains among adults with less than high school education (27.0% to 47.0%, Δ=↑74.4%) and low-income adults (25.9% to 44.2%, Δ=↑74.4%).

Conclusion: Our population health model predicts worsening obesity, diabetes, and CVD that will exacerbate health disparities without targeted health interventions and policies.

Disclosure

D. Kim: None. L. Wang: None. D. Mozaffarian: Research Support; National Institutes of Health, Gates Foundation, Kaiser Permanente Fund, National Association of Chain Drug Stores Foundation, Rockefeller Foundation. Consultant; Acasti Pharma, Inc. Board Member; Beren Therapeutics, Brightseed, Calibrate, Elysium Health, Filtricine, HumanCo, Instacart Health, January Inc., Season Health, Validation Institute, Perfect Day, Tiny Organics. Stock/Shareholder; Calibrate, HumanCo. Other Relationship; UpToDate. J.B. Wong: None.

Funding

NIH/NHLBI (R01HL115189)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.